As of 10:25 on March 25, 2025, the CSI Innovative Drug Industry Index (931152) rose 0.24%, the constituent stocks Zhixiang Jintai (688443) rose 6.28%, Remegen Biotech (688331) rose 4.77%, Haisco (002653) rose 4.06%, Allist (688578) rose 3.33%, and Betta Pharmaceuticals (300558) rose 2.02%. Innovative drug ETF (159992) rose 0.14%, the latest price was 0.72 yuan, and the intraday turnover has reached 66.1601 million yuan, temporarily ranking 1/7 of comparable ETFs, with a turnover rate of 0.56%.

Minsheng Securities said that it actively pays attention to the subdivision direction of AI medical + early tumor screening, with large market space and high barriers, and the continuous upgrading of AI technology is expected to optimize detection performance and achieve application breakthroughs. The commercialization of overseas tumor early screening products has achieved initial results, and domestic attention has been paid to domestic substitution in the upstream of the gene sequencing industry chain and the leading application in the middle and lower reaches. Domestic demand in the CXO sector has bottomed out, overseas demand is stable, and the fulfillment of orders and statements of leading companies will drive valuation repair. In the traditional Chinese medicine sector, traditional Chinese medicine OTC is expected to stabilize with downstream pharmacies. The downstream demand of the blood products industry is booming, and the development potential of the Jingchong industry in the next 3-5 years is great, so we should pay attention to the upward cycle of the industry brought about by the increase in the number of pulp stations and the profit per ton of pulp. The performance of some key companies in the vaccine direction has improved, focusing on the improvement of the 24-year inventory cycle and the expansion of the MCV4 vaccine market. The upstream supply chain of pharmaceuticals focuses on the inflection point of the operation of growing enterprises and the wave of mergers and acquisitions in the life science industry chain in 2025, the fourth-generation sequencing business and the rhythm of large orders in the pharmaceutical industry.

Related products: Innovative drug ETF (159992).